Literature DB >> 3141170

In vitro activity and beta-lactamase stability of LY163892.

E Pelosi1, R Fontana.   

Abstract

Susceptibility testing of clinical isolates of several gram-negative and gram-positive species showed LY163892 to be more active than cefaclor and cephalexin. OXA-2, TEM-1, TEM-2, PSE-1, CEP-1, CARB-3 and SHV-1 beta-lactamases showed similar activity against LY163892 and cefaclor, whereas OXA-1 hydrolyzed the latter more rapidly. Organisms producing these beta-lactamases, but not TEM-2 and CEP-1, appeared to be more susceptible to LY163892 than cephalexin, although cephalexin proved to be more resistant to beta-lactamase activity. Strains producing TEM-2 and CEP-1 were resistant to LY163892, cefaclor and cephalexin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3141170     DOI: 10.1007/bf01962613

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  4 in total

1.  Disc diffusion test for the determination of semi-quantitative substrate profiles of beta-lactamases.

Authors:  J A van de Klundert; M H van Gestel; E van Doorn; R P Mouton
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

2.  In vitro activities of LY163892, cefaclor, and cefuroxime.

Authors:  C C Knapp; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

3.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

4.  beta-Lactamases and beta-lactam resistance in Escherichia coli.

Authors:  G A Jacoby; L Sutton
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

  4 in total
  4 in total

1.  beta-Lactamase stability and in vitro activity of oral cephalosporins against strains possessing well-characterized mechanisms of resistance.

Authors:  C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 2.  Loracarbef. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D McTavish
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

3.  Pharmacokinetics of loracarbef and interaction with acetylcysteine.

Authors:  S Roller; H Lode; I Stelzer; K M Deppermann; M Boeckh; P Koeppe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

4.  Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia.

Authors:  O Müller; K Wettich
Journal:  Infection       Date:  1992 May-Jun       Impact factor: 3.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.